CXCL2 and metabolic syndrome: Both AgNP-exposed models receiving RvE1 and MaR1 treatment demonstrated reduced CXCL-2 protein levels compared to the exposed PBS-treated groups; however, PD1 treatment only reduced the CXCL-2 level in the exposed MetS model (Figure 7A).